ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Resumption of Standard Dose Immunosuppression Following Resolution of BK Viremia Does Not Lead to Viremia Recurrence.

K. Alquadan, A. Santos, M. Casey, T. Ozrazgat-Baslanti, S. Bozorgmehri, J. Gregg, K. Womer.

Medicine, Nephrology, University of Florida, Gainesville, FL

Meeting: 2017 American Transplant Congress

Abstract number: 236

Keywords: Immunosuppression, Kidney transplantation, Polyma virus

Session Information

Session Name: Concurrent Session: Kidney BK Virus

Session Type: Concurrent Session

Date: Monday, May 1, 2017

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:06pm-3:18pm

Location: E451a

Introduction: Reduction of immunosuppression (IS) in response to BK viremia following kidney transplantation prevents the development of BK virus nephropathy, with no apparent increase in acute rejection rates. However, reduced IS is associated with development of donor specific antibodies, which is a risk factor for long term graft failure. It is unknown whether resumption of standard dose IS after viremia resolution can be achieved without viremia recurrence. To answer this question, we developed a protocol of IS reduction followed by resumption of standard dose IS after BK clearance.

Methods: Thirty-six consecutive kidney transplant recipients who developed BK viremia from 7/1/2014 until 12/1/2016 were studied. Upon detection of BK viremia, mycophenolate mofetil (MMF) and tacrolimus were immediately reduced to a daily dose of 1000mg and to trough levels of 3-5 ng/L, respectively. If BKV levels failed to decline progressively after 2 months, MMF was reduced further to a daily dose of 500mg/day, and ultimately discontinued if viremia persisted. After 4 weeks of absent viremia, MMF was increased by 500mg/day every two weeks up to pre-viremia dosage if BKV levels remained negative, followed by increase of tacrolimus trough levels to 5-7 ng/L. If viremia recurred during this increase, IS was reduced back again in this same stepwise fashion, with increase again after 2 months of negative viremia.

Results: The median time from transplant to BK viremia onset was 89 days (range:29-398) and median duration of viremia was 47 days(range:7-332). Mean level of tacrolimus was 8.3+2.7ng/L at onset, 5.3+3.6ng/L at resolution, with a final level of 5.5+2ng/L. Mean daily dose (mg) of MMF at onset was 1570+350, 910+230 at resolution, with a final dose of 1290+470. Two patients (5.5%) developed acute rejection following IS reduction. Two patients (5.5%) have not yet cleared with IS reduction. Only one patient developed low level viremia recurrence (peak 2875 copies/mL) during the period of IS increase and has not yet reached target IS goal (current 252 copies/mL).

Conclusion: Following BK viremia resolution, an increase in IS to pre BK viremia levels can be achieved safely in almost all patients without BK viremia recurrence. Longer-term trials will be needed to determine whether such an approach leads to improved long-term graft survival.

CITATION INFORMATION: Alquadan K, Santos A, Casey M, Ozrazgat-Baslanti T, Bozorgmehri S, Gregg J, Womer K. Resumption of Standard Dose Immunosuppression Following Resolution of BK Viremia Does Not Lead to Viremia Recurrence. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Alquadan K, Santos A, Casey M, Ozrazgat-Baslanti T, Bozorgmehri S, Gregg J, Womer K. Resumption of Standard Dose Immunosuppression Following Resolution of BK Viremia Does Not Lead to Viremia Recurrence. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/resumption-of-standard-dose-immunosuppression-following-resolution-of-bk-viremia-does-not-lead-to-viremia-recurrence/. Accessed May 10, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences